Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Income from Continuing Operations for 16 consecutive years, with 891000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 46.1% to 891000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 10919000.0, a 292.91% decrease, with the full-year FY2025 number at 10919000.0, down 129.87% from a year prior.
  • Income from Continuing Operations was 891000.0 for Q4 2025 at Anika Therapeutics, up from 3175000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15449000.0 in Q4 2023 to a low of 10350000.0 in Q1 2023.
  • A 5-year average of 882600.0 and a median of 2363000.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 204.95% in 2022; the steepest drop was 856.34% in 2022.
  • Anika Therapeutics' Income from Continuing Operations stood at 5793000.0 in 2021, then surged by 204.95% to 6080000.0 in 2022, then soared by 154.1% to 15449000.0 in 2023, then tumbled by 89.3% to 1653000.0 in 2024, then plummeted by 46.1% to 891000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Income from Continuing Operations are 891000.0 (Q4 2025), 3175000.0 (Q3 2025), and 4666000.0 (Q2 2025).